Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Oragenics (NYSE:OGENGet Free Report) in a report issued on Friday. The firm set a “sell” rating on the stock.

Oragenics Trading Up 0.8 %

Shares of NYSE OGEN opened at $0.31 on Friday. Oragenics has a 12-month low of $0.25 and a 12-month high of $4.00. The company has a market cap of $3.77 million, a price-to-earnings ratio of -0.04 and a beta of 0.40. The stock’s 50 day simple moving average is $0.34 and its 200 day simple moving average is $0.55.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.